Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Adriaan IJzerman

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Living Beings

Procedures

Radioligand Assay

Anatomy

CHO Cells

Physiology

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
36
Danhof, Meindert
36
Soudijn, Willem
29
Von Frijtag Drabbe Künzel, Jacobien
27
Beukers, Margot
18
Brussee, Johannes
17
Jacobson, Kenneth
11
van Schaick, EA
11
Mulder-Krieger, Thea
10
van Wijngaarden, Ineke
10
de Groote, Miriam
10
Lorenzen, Anna
10
Heitman, Laura
8
Ye, Kai
7
van Tilburg, Erica
7
Van Helden, Herman

Sign-in to see all Coauthors

Publications

TOP 3
Lane J Robert; Beukers Margot W; Mulder-Krieger Thea; Ijzerman Ad P
The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A(3) adenosine receptor.
Guo Dong; Klaasse Elisabeth; de Vries Henk; Brussee Johannes; Nalos Lukás; Rook Martin B; Vos Marc A; van der Heyden Marcel A G; Ijzerman Adriaan P
Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
Heitman Laura H; Narlawar Rajeshwar; de Vries Henk; Willemsen Milou N; Wolfram Dieter; Brussee Johannes; Ijzerman Adriaan P
Substituted terphenyl compounds as the first class of low molecular weight allosteric inhibitors of the luteinizing hormone receptor.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Adriaan IJzerman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2010: Lane J Robert; Beukers Margot W; Mulder-Krieger Thea; Ijzerman Ad P
The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A(3) adenosine receptor.
Biochemical pharmacology 2010;79(1):48-56.
2009: Guo Dong; Klaasse Elisabeth; de Vries Henk; Brussee Johannes; Nalos Lukás; Rook Martin B; Vos Marc A; van der Heyden Marcel A G; Ijzerman Adriaan P
Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
ChemMedChem 2009;4(10):1722-32.
2009: Heitman Laura H; Narlawar Rajeshwar; de Vries Henk; Willemsen Milou N; Wolfram Dieter; Brussee Johannes; Ijzerman Adriaan P
Substituted terphenyl compounds as the first class of low molecular weight allosteric inhibitors of the luteinizing hormone receptor.
Journal of medicinal chemistry 2009;52(7):2036-42.
2009: Kim Yoonkyung; de Castro Sonia; Gao Zhan-Guo; Ijzerman Adriaan P; Jacobson Kenneth A
Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor.
Journal of medicinal chemistry 2009;52(7):2098-108.
2009: van der Horst Eelke; Okuno Yasushi; Bender Andreas; IJzerman Adriaan P
Substructure mining of GPCR ligands reveals activity-class specific functional groups in an unbiased manner.
Journal of chemical information and modeling 2009;49(2):348-60.
2009: Heitman Laura H; Göblyös Anikó; Zweemer Annelien M; Bakker Renée; Mulder-Krieger Thea; van Veldhoven Jacobus P D; de Vries Henk; Brussee Johannes; Ijzerman Adriaan P
A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor.
Journal of medicinal chemistry 2009;52(4):926-31.
2009: Yuliana Nancy Dewi; Khatib Alfi; Link-Struensee Anne Maria; Ijzerman Adriaan P; Rungkat-Zakaria Fransiska; Choi Young Hae; Verpoorte Robert
Adenosine A1 receptor binding activity of methoxy flavonoids from Orthosiphon stamineus.
Planta medica 2009;75(2):132-6.
2008: Jaakola Veli-Pekka; Griffith Mark T; Hanson Michael A; Cherezov Vadim; Chien Ellen Y T; Lane J Robert; Ijzerman Adriaan P; Stevens Raymond C
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.
Science (New York, N.Y.) 2008;322(5905):1211-7.
2008: Heitman Laura H; Ijzerman Adriaan P
G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for Gnrh, LH, FSH, and GPR54 receptor ligands.
Medicinal research reviews 2008;28(6):975-1011.
2008: Heitman Laura H; van Veldhoven Jacobus P D; Zweemer Annelien M; Ye Kai; Brussee Johannes; IJzerman Adriaan P
False positives in a reporter gene assay: identification and synthesis of substituted N-pyridin-2-ylbenzamides as competitive inhibitors of firefly luciferase.
Journal of medicinal chemistry 2008;51(15):4724-9.
2008: Mantri Monica; de Graaf Olivier; van Veldhoven Jacobus; Göblyös Anikó; von Frijtag Drabbe Künzel Jacobien K; Mulder-Krieger Thea; Link Regina; de Vries Henk; Beukers Margot W; Brussee Johannes; Ijzerman Adriaan P
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.
Journal of medicinal chemistry 2008;51(15):4449-55.
2008: Heitman Laura H; Ye Kai; Oosterom Julia; Ijzerman Adriaan P
Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor.
Molecular pharmacology 2008;73(6):1808-15.
2008: Ye Kai; Vriend Gert; IJzerman Adriaan P
Tracing evolutionary pressure.
Bioinformatics (Oxford, England) 2008;24(7):908-15.
2008: Bonger Kimberly M; van den Berg Richard J B H N; Knijnenburg Annemiek D; Heitman Laura H; Ijzerman Ad P; Oosterom Julia; Timmers Cornelis M; Overkleeft Herman S; van der Marel Gijsbert A
Synthesis and evaluation of homodimeric GnRHR antagonists having a rigid bis-propargylated benzene core.
Bioorganic & medicinal chemistry 2008;16(7):3744-58.
2008: Klaasse Elisabeth C; Ijzerman Adriaan P; de Grip Willem J; Beukers Margot W
Internalization and desensitization of adenosine receptors.
Purinergic signalling 2008;4(1):21-37.
2008: van Veldhoven Jacobus P D; Chang Lisa C W; von Frijtag Drabbe Künzel Jacobien K; Mulder-Krieger Thea; Struensee-Link Regina; Beukers Margot W; Brussee Johannes; IJzerman Adriaan P
A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.
Bioorganic & medicinal chemistry 2008;16(6):2741-52.
2008: Heitman Laura H; Oosterom Julia; Bonger Kimberly M; Timmers Cornelis M; Wiegerinck Peter H G; Ijzerman Adriaan P
[3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor.
Molecular pharmacology 2008;73(2):518-24.
2008: Ye Kai; Anton Feenstra K; Heringa Jaap; Ijzerman Adriaan P; Marchiori Elena
Multi-RELIEF: a method to recognize specificity determining residues from multiple sequence alignments using a Machine-Learning approach for feature weighting.
Bioinformatics (Oxford, England) 2008;24(1):18-25.
2008: Priego Eva-María; Pérez-Pérez María-Jesús; von Frijtag Drabbe Kuenzel Jacobien K; de Vries Henk; Ijzerman Adriaan P; Camarasa María-José; Martín-Santamaría Sonsoles
Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
ChemMedChem 2008;3(1):111-9.
2008: Kazius Jeroen; Wurdinger Kerstin; van Iterson Maarten; Kok Joost; Bäck Thomas; Ijzerman Ad P
GPCR NaVa database: natural variants in human G protein-coupled receptors.
Human mutation 2008;29(1):39-44.
2008: Gao Zhan-Guo; Ye Kai; Göblyös Anikó; Ijzerman Adriaan P; Jacobson Kenneth A
Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000.
BMC pharmacology 2008;8():20.
2007: Bonger Kimberly M; van den Berg Richard J B H N; Heitman Laura H; IJzerman Ad P; Oosterom Julia; Timmers Cornelis M; Overkleeft Herman S; van der Marel Gijsbert A
Synthesis and evaluation of homo-bivalent GnRHR ligands.
Bioorganic & medicinal chemistry 2007;15(14):4841-56.
2007: Soudijn Willem; van Wijngaarden Ineke; Ijzerman Adriaan P
Nicotinic acid receptor subtypes and their ligands.
Medicinal research reviews 2007;27(3):417-33.
2007: Lameijer Eric-Wubbo; Tromp Reynier A; Spanjersberg Ronald F; Brussee Johannes; Ijzerman Adriaan P
Designing active template molecules by combining computational de novo design and human chemist's expertise.
Journal of medicinal chemistry 2007;50(8):1925-32.
2007: Samsonova Elena V; Krause Peter; Bäck Thomas; IJzerman Ad P
Characteristic amino acid combinations in olfactory G protein-coupled receptors.
Proteins 2007;67(1):154-66.
2007: Ye Kai; Kosters Walter A; Ijzerman Adriaan P
An efficient, versatile and scalable pattern growth approach to mine frequent patterns in unaligned protein sequences.
Bioinformatics (Oxford, England) 2007;23(6):687-93.
2007: Chang Lisa C W; von Frijtag Drabbe Künzel Jacobien K; Mulder-Krieger Thea; Westerhout Joost; Spangenberg Thomas; Brussee Johannes; Ijzerman Adriaan P
2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists.
Journal of medicinal chemistry 2007;50(4):828-34.
2007: Li Qilan; Ye Kai; Blad Clara C; den Dulk Hans; Brouwer Jaap; Ijzerman Ad P; Beukers Margot W
ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor.
The Journal of pharmacology and experimental therapeutics 2007;320(2):637-45.
2006: Beukers Margot W; Meurs Illiana; Ijzerman Adriaan P
Structure-affinity relationships of adenosine A2B receptor ligands.
Medicinal research reviews 2006;26(5):667-98.
2006: Samsonova Elena V; Kok Joost N; Ijzerman Ad P
TreeSOM: Cluster analysis in the self-organizing map.
Neural networks : the official journal of the International Neural Network Society 2006;19(6-7):935-49.
2006: Göblyös Anikó; Gao Zhan-Guo; Brussee Johannes; Connestari Roberto; Santiago Sabrina Neves; Ye Kai; Ijzerman Adriaan P; Jacobson Kenneth A
Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.
Journal of medicinal chemistry 2006;49(11):3354-61.
2006: Ye Kai; Lameijer Eric-Wubbo M; Beukers Margot W; Ijzerman Adriaan P
A two-entropies analysis to identify functional positions in the transmembrane region of class A G protein-coupled receptors.
Proteins 2006;63(4):1018-30.
2006: Chang Lisa C W; Spanjersberg Ronald F; von Frijtag Drabbe Künzel Jacobien K; Mulder-Krieger Thea; Brussee Johannes; Ijzerman Adriaan P
2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists.
Journal of medicinal chemistry 2006;49(10):2861-7.
2006: Kazius Jeroen; Nijssen Siegfried; Kok Joost; Bäck Thomas; Ijzerman Adriaan P
Substructure mining using elaborate chemical representation.
Journal of chemical information and modeling 2006;46(2):597-605.
2006: Lameijer Eric-Wubbo; Kok Joost N; Bäck Thomas; Ijzerman Ad P
Mining a chemical database for fragment co-occurrence: discovery of "chemical clichés".
Journal of chemical information and modeling 2006;46(2):553-62.
2006: Lameijer Eric-Wubbo; Kok Joost N; Bäck Thomas; Ijzerman Ad P
The molecule evoluator. An interactive evolutionary algorithm for the design of drug-like molecules.
Journal of chemical information and modeling 2006;46(2):545-52.
2006: Heitman Laura H; Mulder-Krieger Thea; Spanjersberg Ronald F; von Frijtag Drabbe Künzel Jacobien K; Dalpiaz Alessandro; IJzerman Adriaan P
Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist.
British journal of pharmacology 2006;147(5):533-41.
2006: Bond Richard A; Ijzerman Ad P
Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery.
Trends in pharmacological sciences 2006;27(2):92-6.
2005: Klaasse Elisabeth C; van den Hout Gijs; Roerink Sophie F; de Grip Willem J; Ijzerman Ad P; Beukers Margot W
Allosteric modulators affect the internalization of human adenosine A1 receptors.
European journal of pharmacology 2005;522(1-3):1-8.
2005: Beukers Margot W; Ijzerman Adriaan P
Techniques: how to boost GPCR mutagenesis studies using yeast.
Trends in pharmacological sciences 2005;26(10):533-9.
2005: Soudijn Willem; van Wijngaarden Ineke; Ijzerman Adriaan P
Structure-activity relationships of inverse agonists for G-protein-coupled receptors.
Medicinal research reviews 2005;25(4):398-426.
2005: Gao Zhan-Guo; Kim Soo-Kyung; Ijzerman Adriaan P; Jacobson Kenneth A
Allosteric modulation of the adenosine family of receptors.
Mini reviews in medicinal chemistry 2005;5(6):545-53.
2005: Schaddelee Marloes P; Collins Sue D; DeJongh Joost; de Boer Albertus G; Ijzerman Adriaan P; Danhof Meindert
Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain.
European journal of pharmacology 2005;514(2-3):131-40.
2005: Chang Lisa C W; von Frijtag Drabbe Künzel Jacobien K; Mulder-Krieger Thea; Spanjersberg Ronald F; Roerink Sophie F; van den Hout Gijs; Beukers Margot W; Brussee Johannes; Ijzerman Adriaan P
A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.
Journal of medicinal chemistry 2005;48(6):2045-53.
2005: de Ligt Rianne A F; Rivkees Scott A; Lorenzen Anna; Leurs Rob; IJzerman Ad P
A "locked-on," constitutively active mutant of the adenosine A1 receptor.
European journal of pharmacology 2005;510(1-2):1-8.
2005: Göblyös Anikó; Santiago Sabrina Neves; Pietra Daniele; Mulder-Krieger Thea; von Frijtag Drabbe Künzel Jacobien; Brussee Johannes; Ijzerman Adriaan P
Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers.
Bioorganic & medicinal chemistry 2005;13(6):2079-87.
2005: Göblyös Anikó; de Vries Henk; Brussee Johannes; Ijzerman Adriaan P
Synthesis and biological evaluation of a new series of 2,3,5-substituted [1,2,4]-thiadiazoles as modulators of adenosine A1 receptors and their molecular mechanism of action.
Journal of medicinal chemistry 2005;48(4):1145-51.
2005: Tromp Reynier A; Spanjersberg Ronald F; von Frijtag Drabbe Künzel Jacobien K; IJzerman Adriaan P
Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines.
Journal of medicinal chemistry 2005;48(1):321-9.
2005: Schaddelee Marloes P; Read Kevin D; Cleypool Cindy G J; Ijzerman Adriaan P; Danhof Meindert; de Boer Albertus G
Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2005;24(1):59-66.
2004: Chang Lisa C W; Spanjersberg Ronald F; von Frijtag Drabbe Künzel Jacobien K; Mulder-Krieger Thea; van den Hout Gijs; Beukers Margot W; Brussee Johannes; Ijzerman Adriaan P
2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists.
Journal of medicinal chemistry 2004;47(26):6529-40.
2004: Schaddelee M P; Groenendaal D; DeJongh J; Cleypool C G J; IJzerman A P; De Boer A G; Danhof M
Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists.
The Journal of pharmacology and experimental therapeutics 2004;311(3):1138-46.
2004: Chang Lisa C W; Brussee Johannes; Ijzerman Adriaan P
Non-xanthine antagonists for the adenosine A1 receptor.
Chemistry & biodiversity 2004;1(11):1591-626.
2004: Schaddelee Marloes P; Dejongh Joost; Collins Sue D; de Boer Albertus G; Ijzerman Adriaan P; Danhof Meindert
Population pharmacokinetic-pharmacodynamic modelling of the anti-hyperalgesic effect of 5'deoxy-N6-cylopentyladenosine in the mononeuropathic rat.
European journal of pharmacology 2004;504(1-2):7-15.
2004: Cordeaux Yolande; Ijzerman Adriaan P; Hill Stephen J
Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation.
British journal of pharmacology 2004;143(6):705-14.
2004: Tromp Reynier A; van Ameijde Susan; Pütz Claudia; Sundermann Corinna; Sundermann Bernd; von Frijtag Drabbe Künzel Jacobien K; IJzerman Adriaan P
Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups.
Journal of medicinal chemistry 2004;47(22):5441-50.
2004: Soudijn Willem; Van Wijngaarden Ineke; IJzerman Ad P
Allosteric modulation of G protein-coupled receptors: perspectives and recent developments.
Drug discovery today 2004;9(17):752-8.
2004: Klaasse Elisabeth; de Ligt Rianne A F; Roerink Sophie F; Lorenzen Anna; Milligan Graeme; Leurs Rob; IJzerman Ad P
Allosteric modulation and constitutive activity of fusion proteins between the adenosine A1 receptor and different 351Cys-mutated Gi alpha-subunits.
European journal of pharmacology 2004;499(1-2):91-8.
2004: Beukers Margot W; Chang Lisa C W; von Frijtag Drabbe Künzel Jacobien K; Mulder-Krieger Thea; Spanjersberg Ronald F; Brussee Johannes; IJzerman Ad P
New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine.
Journal of medicinal chemistry 2004;47(15):3707-9.
2004: Wittendorp Maria C; von Frijtag Drabbe Künzel Jacobien; Ijzerman Adriaan P; Boddeke Hendrikus W G M; Biber Knut
The mouse brain adenosine A1 receptor: functional expression and pharmacology.
European journal of pharmacology 2004;487(1-3):73-9.
2004: Beukers Margot W; van Oppenraaij Joris; van der Hoorn Patrick P W; Blad Clara C; den Dulk Hans; Brouwer Jaap; IJzerman Adriaan P
Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations.
Molecular pharmacology 2004;65(3):702-10.
2004: van den Nieuwendijk Adrianus M C H; Pietra Daniele; Heitman Laura; Göblyös Anikó; IJzerman Adriaan P
Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors.
Journal of medicinal chemistry 2004;47(3):663-72.
2004: de Ligt Rianne A F; van der Klein Pieter A M; von Frijtag Drabbe Künzel Jacobien K; Lorenzen Anna; Ait El Maate Fatna; Fujikawa Shelly; van Westhoven Rosemarijn; van den Hoven Thijs; Brussee Johannes; IJzerman Ad P
Synthesis and biological evaluation of disubstituted N6-cyclopentyladenine analogues: the search for a neutral antagonist with high affinity for the adenosine A1 receptor.
Bioorganic & medicinal chemistry 2004;12(1):139-49.
2003: Bueters Tjerk J H; van Duivenvoorde Leonie M; Danhof Meindert; IJzerman Ad P; van Helden Herman P M
Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree.
European journal of pharmacology 2003;481(2-3):141-6.
2003: Schaddelee Marloes P; Voorwinden Heleen L; Groenendaal Dorien; Hersey Anne; Ijzerman Adriaan P; Danhof Meindert; De Boer Albertus G
Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2003;20(3):347-56.
2003: Bueters Tjerk J H; IJzerman Ad P; van Helden Herman P M; Danhof Meindert
Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats.
Toxicology and applied pharmacology 2003;192(1):86-94.
2003: van Herk T; Brussee J; van den Nieuwendijk A M C H; van der Klein P A M; IJzerman A P; Stannek C; Burmeister A; Lorenzen A
Pyrazole derivatives as partial agonists for the nicotinic acid receptor.
Journal of medicinal chemistry 2003;46(18):3945-51.
2003: Harrison Patrick K; Bueters Tjerk J H; Ijzerman Adriaan P; van Helden Herman P M; Tattersall John E H
Partial adenosine A(1) receptor agonists inhibit sarin-induced epileptiform activity in the hippocampal slice.
European journal of pharmacology 2003;471(2):97-104.
2003: Bueters Tjerk J H; van Helden Herman P M; IJzerman Adriaan P; Danhof Meindert
Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action.
Neuroscience letters 2003;343(1):57-61.
2003: Schaddelee Marloes P; Voorwinden Heleen L; van Tilburg Erica W; Pateman Tony J; Ijzerman Adriaan P; Danhof Meindert; de Boer Albertus G
Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2003;19(1):13-22.
2003: van Tilburg Erica W; Gremmen Matty; von Frijtag Drabbe Künzel Jacobien; de Groote Miriam; IJzerman Ad P
2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor.
Bioorganic & medicinal chemistry 2003;11(10):2183-92.
2003: Beukers Margot W; Wanner Martin J; Von Frijtag Drabbe Künzel Jacobien K; Klaasse Elisabeth C; IJzerman Adriaan P; Koomen Gerrit-Jan
N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor.
Journal of medicinal chemistry 2003;46(8):1492-503.
2003: Deghati Paymaneh Y F; Borghini Alice; van den Nieuwendijk Adrianus M C H; Dissen-de Groote Miriam; IJzerman Adriaan P
Inhibition of nucleoside transport by new analogues of nitrobenzylthioinosine.
Bioorganic & medicinal chemistry 2003;11(6):899-908.
2003: Bueters Tjerk J H; Joosen Marloes J A; van Helden Herman P M; Ijzerman Ad P; Danhof Meindert
Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin.
The Journal of pharmacology and experimental therapeutics 2003;304(3):1307-13.
2003: Gao Zhan-Guo; Melman Neli; Erdmann Andreas; Kim Seong Gon; Müller Christa E; IJzerman Adriaan P; Jacobson Kenneth A
Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors.
Biochemical pharmacology 2003;65(4):525-34.
2003: Soudjin Willem; van Wijngaarden Ineke; IJzerman A P
Stereoselectivity of drug-receptor interactions.
IDrugs : the investigational drugs journal 2003;6(1):43-56.
2003: Soudijn Willem; van Wijngaarden Ineke; IJzerman Ad P
Medicinal chemistry of adenosine A1 receptor ligands.
Current topics in medicinal chemistry 2003;3(4):355-67.
2002: Bueters Tjerk J H; van Helden Herman P M; Danhof Meindert; IJzerman Ad P
Effects of the adenosine A1 receptor allosteric modulators PD 81,723 and LUF 5484 on the striatal acetylcholine release.
European journal of pharmacology 2002;454(2-3):177-82.
2002: Bueters Tjerk J H; Groen Bas; Danhof Meindert; IJzerman Ad P; Van Helden Herman P M
Therapeutic efficacy of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) against organophosphate intoxication.
Archives of toxicology 2002;76(11):650-6.
2002: Lorenzen Anna; Beukers Margot W; van der Graaf Piet Hein; Lang Heidrun; van Muijlwijk-Koezen Jacqueline; de Groote Miriam; Menge Wiro; Schwabe Ulrich; IJzerman Adriaan P
Modulation of agonist responses at the A(1) adenosine receptor by an irreversible antagonist, receptor-G protein uncoupling and by the G protein activation state.
Biochemical pharmacology 2002;64(8):1251-65.
2002: Soudijn Willem; van Wijngaarden Ineke; IJzerman Ad P
Allosteric modulation of G protein-coupled receptors.
Current opinion in drug discovery & development 2002;5(5):749-55.
2002: Priego Eva-María; von Frijtag Drabbe Kuenzel Jacobien; IJzerman Ad P; Camarasa María-José; Pérez-Pérez María-Jesús
Pyrido[2,1-f]purine-2,4-dione derivatives as a novel class of highly potent human A(3) adenosine receptor antagonists.
Journal of medicinal chemistry 2002;45(16):3337-44.
2002: Dalpiaz Alessandro; Pavan Barbara; Ngos Françoise Ngo; Franchetti Palmarisa; IJzerman Adriaan P
Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis.
European journal of pharmacology 2002;448(2-3):123-31.
2002: Gao Zhan-Guo; Kim Seong Gon; Soltysiak Kelly A; Melman Neli; IJzerman Adriaan P; Jacobson Kenneth A
Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives.
Molecular pharmacology 2002;62(1):81-9.
2002: Van Calenbergh Serge; Link Andreas; Fujikawa Shelly; de Ligt Rianne A F; Vanheusden Veerle; Golisade Abolfasl; Blaton Norbert M; Rozenski Jef; IJzerman Adriaan P; Herdewijn Piet
5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists.
Journal of medicinal chemistry 2002;45(9):1845-52.
2002: Del Carmine Renata; Ambrosio Caterina; Sbraccia Maria; Cotecchia Susanna; Ijzerman Adriaan P; Costa Tommaso
Mutations inducing divergent shifts of constitutive activity reveal different modes of binding among catecholamine analogues to the beta(2)-adrenergic receptor.
British journal of pharmacology 2002;135(7):1715-22.
2002: Schrier S Mariëtte; Florea Bogdan I; Mulder Gerard J; Nagelkerke J Fred; IJzerman Ad P
Apoptosis induced by extracellular ATP in the mouse neuroblastoma cell line N1E-115: studies on involvement of P2 receptors and adenosine.
Biochemical pharmacology 2002;63(6):1119-26.
2002: den Haan Joke M M; Mutis Tuna; Blokland Els; IJzerman Ad P; Goulmy Els
General T-cell receptor antagonists to immunomodulate HLA-A2-restricted minor histocompatibility antigen HA-1-specific T-cell responses.
Blood 2002;99(3):985-92.
2002: van Tilburg Erica W; von Frijtag Drabbe Kunzel Jacobien; de Groote Miriam; IJzerman Ad P
2,5'-Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A(1), A(2A), and A(3) receptor.
Journal of medicinal chemistry 2002;45(2):420-9.
2002: de Ligt Rianne A F; IJzerman Ad P
Intrinsic activity at adenosine A1 receptors: partial and inverse agonism.
Current pharmaceutical design 2002;8(26):2333-44.
2001: Fredholm B B; IJzerman A P; Jacobson K A; Klotz K N; Linden J
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.
Pharmacological reviews 2001;53(4):527-52.
2001: Gao Z G; Van Muijlwijk-Koezen J E; Chen A; Müller C E; Ijzerman A P; Jacobson K A
Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives.
Molecular pharmacology 2001;60(5):1057-63.
2001: van Tilburg E W; van der Klein P A; von Frijtag Drabbe Künzel J; de Groote M; Stannek C; Lorenzen A; IJzerman A P
5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors.
Journal of medicinal chemistry 2001;44(18):2966-75.
2001: van Tilburg E W; van der Klein P A; de Groote M; Beukers M W; IJzerman A P
Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor.
Bioorganic & medicinal chemistry letters 2001;11(15):2017-9.
2001: van Muijlwijk-Koezen J E; Timmerman H; van der Sluis R P; van de Stolpe A C; Menge W M; Beukers M W; van der Graaf P H; de Groote M; IJzerman A P
Synthesis and use of FSCPX, an irreversible adenosine A1 antagonist, as a 'receptor knock-down' tool.
Bioorganic & medicinal chemistry letters 2001;11(6):815-8.
2001: van Muijlwijk-Koezen J E; Timmerman H; Vollinga R C; Frijtag von Drabbe Künzel J; de Groote M; Visser S; IJzerman A P
Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists.
Journal of medicinal chemistry 2001;44(5):749-62.
2001: Schrier S M; van Tilburg E W; van der Meulen H; Ijzerman A P; Mulder G J; Nagelkerke J F
Extracellular adenosine-induced apoptosis in mouse neuroblastoma cells: studies on involvement of adenosine receptors and adenosine uptake.
Biochemical pharmacology 2001;61(4):417-25.
2001: Ijzerman A; Kourounakis A; van der Klein P
Allosteric modulation of G protein-coupled receptors.
Farmaco (Società chimica italiana : 1989) 2001;56(1-2):67-70.
2001: Kourounakis A; Visser C; de Groote M; IJzerman A P
Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor.
Biochemical pharmacology 2001;61(2):137-44.
2001: van Muijlwijk-Koezen J E; Timmerman H; Ijzerman A P
The adenosine A3 receptor and its ligands.
Progress in medicinal chemistry 2001;38():61-113.
2000: Beukers M W; den Dulk H; van Tilburg E W; Brouwer J; Ijzerman A P
Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine.
Molecular pharmacology 2000;58(6):1349-56.
2000: Wanner M J; Von Frijtag Drabbe Künzel J K; Ijzerman A P; Koomen G J
2-Nitro analogues of adenosine and 1-deazaadenosine: synthesis and binding studies at the adenosine A1, A2A and A3 receptor subtypes.
Bioorganic & medicinal chemistry letters 2000;10(18):2141-4.
2000: Gao Z G; Ijzerman A P
Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions.
Biochemical pharmacology 2000;60(5):669-76.
2000: Gao Z G; Jiang Q; Jacobson K A; Ijzerman A P
Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation.
Biochemical pharmacology 2000;60(5):661-8.
2000: Garrido M; Gubbens-Stibbe J; Tukker E; Cox E; von Frijtag J; Künzel D; IJzerman A; Danhof M; van der Graaf P H
Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor "knockdown" in vivo.
Pharmaceutical research 2000;17(6):653-9.
2000: van Muijlwijk-Koezen J E; Timmerman H; van der Goot H; Menge W M; Frijtag Von Drabbe Künzel J; de Groote M; IJzerman A P
Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor.
Journal of medicinal chemistry 2000;43(11):2227-38.
2000: de Ligt R A; Kourounakis A P; IJzerman A P
Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery.
British journal of pharmacology 2000;130(1):1-12.
2000: Ingkaninan K; IJzerman A P; Verpoorte R
Luteolin, a compound with adenosine A(1) receptor-binding activity, and chromone and dihydronaphthalenone constituents from Senna siamea.
Journal of natural products 2000;63(3):315-7.
2000: Vittori S; Lorenzen A; Stannek C; Costanzi S; Volpini R; IJzerman A P; Kunzel J K; Cristalli G
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor.
Journal of medicinal chemistry 2000;43(2):250-60.
2000: Schier S M; Ijzerman A P; Mulder G J; Nagelkerke J F
Adenosine-induced caspase activity in N1E-115 cells.
Advances in experimental medicine and biology 2000;486():223-6.
1999: Ingkaninan K; Ijzerman A P; Taesotikult T; Verpoorte R
Isolation of opioid-active compounds from Tabernaemontana pachysiphon leaves.
The Journal of pharmacy and pharmacology 1999;51(12):1441-6.
1999: Beukers M W; Kristiansen I; IJzerman A P; Edvardsen I
TinyGRAP database: a bioinformatics tool to mine G-protein-coupled receptor mutant data.
Trends in pharmacological sciences 1999;20(12):475-7.
1999: Zuurmond H M; Hessling J; Blüml K; Lohse M; Ijzerman A P
Study of interaction between agonists and asn293 in helix VI of human beta(2)-adrenergic receptor.
Molecular pharmacology 1999;56(5):909-16.
1999: van der Klein P A; Kourounakis A P; IJzerman A P
Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding.
Journal of medicinal chemistry 1999;42(18):3629-35.
1999: Van der Graaf P H; Van Schaick E A; Visser S A; De Greef H J; Ijzerman A P; Danhof M
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.
The Journal of pharmacology and experimental therapeutics 1999;290(2):702-9.
1999: Ingkaninan K; von Frijtag Drabbe Künzel J K; IJzerman A P; Verpoorte R
Interference of linoleic acid fraction in some receptor binding assays.
Journal of natural products 1999;62(6):912-4.
1999: van Tilburg E W; von Frijtag Drabbe Künzel J; de Groote M; Vollinga R C; Lorenzen A; IJzerman A P
N6,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor.
Journal of medicinal chemistry 1999;42(8):1393-400.
1999: de Zwart M; Kourounakis A; Kooijman H; Spek A L; Link R; von Frijtag Drabbe Künzel J K; IJzerman A P
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
Journal of medicinal chemistry 1999;42(8):1384-92.
1998: Pavan B; IJzerman A P
Processing of adenosine receptor agonists in rat and human whole blood.
Biochemical pharmacology 1998;56(12):1625-32.
1998: Dalpiaz A; Townsend-Nicholson A; Beukers M W; Schofield P R; IJzerman A P
Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors.
Biochemical pharmacology 1998;56(11):1437-45.
1998: van Muijlwijk-Koezen J E; Timmerman H; Link R; van der Goot H; Ijzerman A P
A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds.
Journal of medicinal chemistry 1998;41(21):3994-4000.
1998: van Muijlwijk-Koezen J E; Timmerman H; Link R; van der Goot H; IJzerman A P
A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives.
Journal of medicinal chemistry 1998;41(21):3987-93.
1998: van Schaick E A; Zuideveld K P; Tukker H E; Langemeijer M W; Ijzerman A P; Danhof M
Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action.
The Journal of pharmacology and experimental therapeutics 1998;287(1):21-30.
1998: Kim Y C; de Zwart M; Chang L; Moro S; von Frijtag Drabbe Künzel J K; Melman N; IJzerman A P; Jacobson K A
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.
Journal of medicinal chemistry 1998;41(15):2835-45.
1998: de Zwart M; Link R; von Frijtag Drabbe Künzel J K; Cristalli G; Jacobson K A; Townsend-Nicholson A; IJzerman A P
A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists.
Nucleosides & nucleotides 1998;17(6):969-85.
1998: van Schaick E A; Tukker H E; Roelen H C; IJzerman A P; Danhof M
Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats.
British journal of pharmacology 1998;124(3):607-18.
1998: Bouwstra J A; Gooris G S; Dubbelaar F E; Weerheim A M; Ijzerman A P; Ponec M
Role of ceramide 1 in the molecular organization of the stratum corneum lipids.
Journal of lipid research 1998;39(1):186-96.
1998: van der Wenden E M; Carnielli M; Roelen H C; Lorenzen A; von Frijtag Drabbe Künzel J K; IJzerman A P
5'-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor.
Journal of medicinal chemistry 1998;41(1):102-8.
1997: van Schaick E A; de Greef H J; Ijzerman A P; Danhof M
Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists.
Journal of pharmacokinetics and biopharmaceutics 1997;25(6):673-94.
1997: van Schaick E A; Kulkarni C; von Frijtag Drabbe Künzel J K; Mathôt R A; Cristalli G; IJzerman A P; Danhof M
Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects.
Naunyn-Schmiedeberg's archives of pharmacology 1997;356(6):827-37.
1997: Van Calenbergh S; von Frijtag Drabbe Künzel J K; Blaton N M; Peeters O M; Rozenski J; Van Aerschot A; De Bruyn A; De Keukeleire D; IJzerman A P; Herdewijn P
N6-cyclopentyl-3'-substituted-xylofuranosyladenosines: a new class of non-xanthine adenosine A1 receptor antagonists.
Journal of medicinal chemistry 1997;40(23):3765-72.
1997: Van Der Graaf P H; Van Schaick E A; Math-ot R A; Ijzerman A P; Danhof M
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors.
The Journal of pharmacology and experimental therapeutics 1997;283(2):809-16.
1997: Van Schaick E A; Math-ot R A; Gubbens-Stibbe J M; Langemeijer M W; Roelen H C; Ijzerman A P; Danhof M
8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo.
The Journal of pharmacology and experimental therapeutics 1997;283(2):800-8.
1997: van Schaick E A; de Greef H J; Langemeijer M W; Sheehan M J; IJzerman A P; Danhof M
Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats.
British journal of pharmacology 1997;122(3):525-33.
1997: Lorenzen A; Sebastião A M; Sellink A; Vogt H; Schwabe U; Ribeiro J A; IJzerman A P
Biological activities of N6,C8-disubstituted adenosine derivatives as partial agonists at rat brain adenosine A1 receptors.
European journal of pharmacology 1997;334(2-3):299-307.
1997: Kuipers W; Oliveira L; Vriend G; Ijzerman A P
Identification of class-determining residues in G protein-coupled receptors by sequence analysis.
Receptors & channels 1997;5(3-4):159-74.
1996: Mathot R A; Wenden E M; Soudijn W; Breimer D D; Ijzerman A P; Danhof M
Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo.
The Journal of pharmacology and experimental therapeutics 1996;279(3):1439-46.
1996: IJzerman A P; Von Frijtag Drabbe Künzel J K; Kim J; Jiang Q; Jacobson K A
Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition.
European journal of pharmacology 1996;310(2-3):269-72.
1996: Van Schaick E A; Jacobson K A; Kim H O; IJzerman A P; Danhof M
Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats.
European journal of pharmacology 1996;308(3):311-4.
1996: Mathoôt R A; Soudijn W; Breimer D D; Ijzerman A P; Danhof M
Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo.
British journal of pharmacology 1996;118(2):369-77.
1996: Roelen H; Veldman N; Spek A L; von Frijtag Drabbe Künzel J; Mathôt R A; IJzerman A P
N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors.
Journal of medicinal chemistry 1996;39(7):1463-71.
1995: Mathôt R A; Van der Wenden E M; Soudijn W; IJzerman A P; Danhof M
Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo.
British journal of pharmacology 1995;116(3):1957-64.
1995: Mathôt R A; Gubbens-Stibbe J M; Soudijn W; Jacobson K A; Ijzerman A P; Danhof M
Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.
The Journal of pharmacology and experimental therapeutics 1995;275(1):245-53.
1995: van der Wenden E M; von Frijtag Drabbe Künzel J K; Mathôt R A; Danhof M; IJzerman A P; Soudijn W
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.
Journal of medicinal chemistry 1995;38(20):4000-6.
1995: Van der Wenden E M; Hartog-Witte H R; Roelen H C; von Frijtag Drabbe Künzel J K; Pirovano I M; Mathôt R A; Danhof M; Van Aerschot A; Lidaks M J; IJzerman A P
8-substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor.
European journal of pharmacology 1995;290(3):189-99.
1995: Appel S; Mathôt R A; Langemeijer M W; IJzerman A P; Danhof M
Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline.
British journal of pharmacology 1995;115(7):1253-9.
1995: Kuipers W; van Wijngaarden I; Kruse C G; ter Horst-van Amstel M; Tulp M T; IJzerman A P
N4-unsubstituted N1-arylpiperazines as high-affinity 5-HT1A receptor ligands.
Journal of medicinal chemistry 1995;38(11):1942-54.
1995: Beukers M W; Kerkhof C J; van Rhee M A; Ardanuy U; Gurgel C; Widjaja H; Nickel P; IJzerman A P; Soudijn W
Suramin analogs, divalent cations and ATP gamma S as inhibitors of ecto-ATPase.
Naunyn-Schmiedeberg's archives of pharmacology 1995;351(5):523-8.
1995: Mathôt R A; Van den Aarsen B C; Soudijn W; Breimer D D; Ijzerman A P; Danhof M
Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats.
The Journal of pharmacology and experimental therapeutics 1995;273(1):405-14.
1995: Mathôt R A; Cleton A; Soudijn W; IJzerman A P; Danhof M
Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats.
British journal of pharmacology 1995;114(4):761-8.
1995: van der Wenden E M; Price S L; Apaya R P; IJzerman A P; Soudijn W
Relative binding orientations of adenosine A1 receptor ligands--a test case for Distributed Multipole Analysis in medicinal chemistry.
Journal of computer-aided molecular design 1995;9(1):44-54.
1994: IJzerman A P; van der Wenden E M; von Frijtag Drabbe Künzel J K; Mathôt R A; Danhof M; Borea P A; Varani K
Partial agonism of theophylline-7-riboside on adenosine receptors.
Naunyn-Schmiedeberg's archives of pharmacology 1994;350(6):638-45.
1994: Van Der Bent A; Ijzerman A P; Soudijn W
Molecular modelling of CCK-A receptors.
Drug design and discovery 1994;12(2):129-48.
1994: Irth H; Cleton A; Mathôt R A; Danhof M; IJzerman A P; Tjaden U R; van der Greef J
Liquid chromatographic determination of the adenosine receptor agonist CGS 21680 in blood using on-line solid-phase extraction on a phenylboronic acid support and fluorescence detection.
Journal of chromatography. B, Biomedical applications 1994;658(1):207-12.
1994: Mathôt R A; Van den Aarsen B C; von Frijtag Drabble Künzel J K; Danhof M; Ijzerman A P
Assessment of the enantiomeric purity of R- and S-N6-phenylisopropyladenosine (PIA): implications for adenosine receptor subclassification.
Naunyn-Schmiedeberg's archives of pharmacology 1994;350(1):109-12.
1994: van Galen P J; van Bergen A H; Gallo-Rodriguez C; Melman N; Olah M E; IJzerman A P; Stiles G L; Jacobson K A
A binding site model and structure-activity relationships for the rat A3 adenosine receptor.
Molecular pharmacology 1994;45(6):1101-11.
1994: IJzerman A P; van der Wenden E M; van Galen P J; Jacobson K A
Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor.
European journal of pharmacology 1994;268(1):95-104.
1994: van Rhee A M; van der Heijden M P; Beukers M W; IJzerman A P; Soudijn W; Nickel P
Novel competitive antagonists for P2 purinoceptors.
European journal of pharmacology 1994;268(1):1-7.
1994: Kuipers W; Van Wijngaarden I; Ijzerman A P
A model of the serotonin 5-HT1A receptor: agonist and antagonist binding sites.
Drug design and discovery 1994;11(3):231-49.
1994: Mathôt R A; van Schaick E A; Langemeijer M W; Soudijn W; Breimer D D; Ijzerman A P; Danhof M
Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat.
The Journal of pharmacology and experimental therapeutics 1994;268(2):616-24.
1994: Beukers M W; Kerkhof C J; IJzerman A P; Soudijn W
Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016.
European journal of pharmacology 1994;266(1):57-62.
1993: Beukers M W; Pirovano I M; van Weert A; Kerkhof C J; IJzerman A P; Soudijn W
Characterization of ecto-ATPase on human blood cells. A physiological role in platelet aggregation?
Biochemical pharmacology 1993;46(11):1959-66.
1993: Mathôt R A; Appel S; van Schaick E A; Soudijn W; IJzerman A P; Danhof M
High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats.
Journal of chromatography 1993;620(1):113-20.
1993: van Rhee A M; van Winden E C; Nagelkerke J F; de Bont H J; IJzerman A P; Soudijn W
Binding of the radioligand [35S]adenosine 5'-O-(2-thiodiphosphate) and intracellular calcium response in rat liver parenchymal cells.
Biochemical pharmacology 1993;45(4):801-7.
1992: Van der Bent A; Ter Laak A M; IJzerman A P; Soudijn W
Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists.
European journal of pharmacology 1992;226(4):327-34.
1992: IJzerman A P; Kruidering M; van Weert A; van Belle H; Janssen C
[3H]R75231--a new radioligand for the nitrobenzylthioinosine sensitive nucleoside transport proteins. Characterization of (+/-)-[3H]R75231 binding to calf lung membranes, stereospecificity of its two stereoisomers, and comparison with [3H]nitrobenzylthioinosine binding.
Naunyn-Schmiedeberg's archives of pharmacology 1992;345(5):558-63.
1992: van der Bent A; Blommaert A G; Melman C T; IJzerman A P; van Wijngaarden I; Soudijn W
Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
Journal of medicinal chemistry 1992;35(6):1042-9.
1992: Ijzerman A P; Melman C T
Chemical modification of cholecystokinin-A receptors in rat pancreatic membranes.
European journal of biochemistry / FEBS 1992;203(3):521-6.
1992: van der Wenden E M; Ijzerman A P; Soudijn W
A steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptor.
Journal of medicinal chemistry 1992;35(4):629-35.
1992: Garritsen A; Beukers M W; IJzerman A P; Cragoe E J; Soudijn W
The mode of interaction of amiloride and some of its analogues with the adenosine A1 receptor.
Neurochemistry international 1992;20(2):207-13.
1992: IJzerman A P; Van Galen P J; Jacobson K A
Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptor.
Drug design and discovery 1992;9(1):49-67.
1991: Van der Wenden E M; Van Galen P J; IJzerman A P; Soudijn W
Mapping the xanthine C8-region of the adenosine A1 receptor with computer graphics.
European journal of pharmacology 1991;206(4):315-23.
1991: van Galen P J; Nissen P; van Wijngaarden I; IJzerman A P; Soudijn W
1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists.
Journal of medicinal chemistry 1991;34(3):1202-6.
1991: IJzerman A P; Voorschuur A; Kruidering M; Pirovano I M; Van Belle H; Janssen C
Radioligand binding studies on the nucleoside transport protein.
Advances in experimental medicine and biology 1991;309A():411-4.
1991: Garritsen A; Ijzerman A P; Tulp M T; Cragoe E J; Soudijn W
Receptor binding profiles of amiloride analogues provide no evidence for a link between receptors and the Na+/H+ exchanger, but indicate a common structure on receptor proteins.
Journal of receptor research 1991;11(6):891-907.
1990: Pirovano I M; Van Belle H; Ijzerman A P
Inhibition of nucleoside uptake in human erythrocytes by a new series of compounds related to lidoflazine and mioflazine.
European journal of pharmacology 1990;189(6):419-22.
1990: IJzerman A P; Voorschuur A H
The relationship between ionization and affinity of nucleoside transport inhibitors.
Naunyn-Schmiedeberg's archives of pharmacology 1990;342(3):336-41.
1990: Garritsen A; Ijzerman A P; Beukers M W; Soudijn W
Chemical modification of adenosine A1 receptors. Implications for the interaction with R-PIA, DPCPX and amiloride.
Biochemical pharmacology 1990;40(4):835-42.
1990: Garritsen A; Ijzerman A P; Beukers M W; Cragoe E J; Soudijn W
Interaction of amiloride and its analogues with adenosine A1 receptors in calf brain.
Biochemical pharmacology 1990;40(4):827-34.
1990: van Galen P J; van Vlijmen H W; IJzerman A P; Soudijn W
A model for the antagonist binding site on the adenosine A1 receptor, based on steric, electrostatic, and hydrophobic properties.
Journal of medicinal chemistry 1990;33(6):1708-13.
1989: Ijzerman A P; Thedinga K H; Custers A F; Hoos B; Van Belle H
Inhibition of nucleoside transport by a new series of compounds related to lidoflazine and mioflazine.
European journal of pharmacology 1989;172(3):273-81.
1989: van Vlijmen H W; IJzerman A P
Molecular modeling of a putative antagonist binding site on helix III of the beta-adrenoceptor.
Journal of computer-aided molecular design 1989;3(2):165-74.
1989: Pirovano I M; IJzerman A P; Van Galen P J; Soudijn W
Influence of the molecular structure of N6-(omega-aminoalkyl)adenosines on adenosine receptor affinity and intrinsic activity.
European journal of pharmacology 1989;172(2):185-93.
1989: Van Galen P J; Leusen F J; IJzerman A P; Soudijn W
Mapping the N6-region of the adenosine A1 receptor with computer graphics.
European journal of pharmacology 1989;172(1):19-27.
1989: IJzerman A P; Menkveld G J; Thedinga K H
A refined method for the photoaffinity labelling of the nitrobenzylthioinosine-sensitive nucleoside transport protein: application to cell membranes of calf lung tissue.
Biochimica et biophysica acta 1989;979(2):153-6.
1989: Garritsen A; Ijzerman A P; Soudijn W
Adenosine-A1 receptors are not coupled to Ca2+ uptake in rat brain synaptosomes.
Biochemical pharmacology 1989;38(4):693-5.
1988: IJzerman A P
Limiting solubilities and ionization constants of sparingly soluble compounds: determination from aqueous potentiometric titration data only.
Pharmaceutical research 1988;5(12):772-5.
1988: IJzerman A P; van Vlijmen H W
A molecular graphics study exploring a putative ligand binding site of the beta-adrenoceptor.
Journal of computer-aided molecular design 1988;2(1):43-53.
1988: Garritsen A; Ijzerman A P; Soudijn W
[3H]batrachotoxinin-A 20-alpha-benzoate binding to sodium channels in rat brain: sensitivity to tetrodotoxin and divalent cations.
European journal of pharmacology 1988;145(3):261-6.
1987: Ijzerman A P; Nagesser A; Garritsen A
The membrane stabilizing activity of beta-adrenoceptor ligands. Quantitative evaluation of the interaction of phenoxypropanolamines with the [3H]batrachotoxinin A 20-alpha-benzoate binding site on voltage-sensitive sodium channels in rat brain.
Biochemical pharmacology 1987;36(24):4239-44.
1987: van Galen P J; Ijzerman A P; Soudijn W
Adenosine derivatives with N6-alkyl, -alkylamine or -alkyladenosine substituents as probes for the A1-receptor.
FEBS letters 1987;223(1):197-201.

Sign-in to see more